BlackRock Health Sciences Term Trust (BMEZ) To Go Ex-Dividend on December 16th

BlackRock Health Sciences Term Trust (NYSE:BMEZ) announced a monthly dividend on Friday, December 6th,NASDAQ Dividends reports. Investors of record on Monday, December 16th will be given a dividend of 0.1781 per share on Monday, December 23rd. This represents a $2.14 annualized dividend and a yield of 13.81%. The ex-dividend date of this dividend is Monday, December 16th.

BlackRock Health Sciences Term Trust has raised its dividend payment by an average of 20.7% per year over the last three years.

BlackRock Health Sciences Term Trust Stock Down 0.1 %

BMEZ traded down 0.02 during trading hours on Friday, hitting 15.48. The company’s stock had a trading volume of 360,200 shares, compared to its average volume of 277,112. BlackRock Health Sciences Term Trust has a fifty-two week low of 14.38 and a fifty-two week high of 16.59. The company has a 50-day simple moving average of 15.61 and a 200 day simple moving average of 15.62.

Insider Buying and Selling

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. acquired 29,795 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were acquired at an average price of 15.81 per share, with a total value of 471,058.95. Following the completion of the transaction, the insider now directly owns 20,750,913 shares in the company, valued at 328,071,934.53. This trade represents a 0.14 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders acquired 99,630 shares of company stock valued at $1,585,113.

About BlackRock Health Sciences Term Trust

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.